The multicenter, double-blind, placebo-controlled, randomized clinical trial included 56 children. The study subjects received 1.5 to 2.5 mg/kg of thalidomide or placebo once daily for eight weeks. The study found that a significantly higher number of children treated with thalidomide reached clinical remission, as opposed to the group treated with the placebo.
The researchers recommend replication of the study to confirm the clinical value of thalidomide.
More Articles on Gastroenterology:
AAAS Names Dr. Bishr Omary 2013 Fellow
4 Things to Know About Patient & Physician Shared Decision-Making in Gastroenterology
Study: Endoscopic Therapy vs. Surgery as Treatment for Early Esophageal Cancer
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
